Clinical Roundup Cedars-Sinai researchers find two potential treatments that improve outcomes in recurrent prostate cancer October 27, 2023Vol.49 No.40
Clinical Roundup MRI scan could predict radiation side effects for prostate cancer October 20, 2023Vol.49 No.39
Clinical Roundup Phase II study of BXCL701 + Keytruda in small cell neuroendocrine prostate cancer shows positive OS results October 13, 2023Vol.49 No.38
Clinical Roundup USC study identifies mutations in 11 genes associated with aggressive prostate cancer September 22, 2023Vol.49 No.35
Drugs & Targets FDA approves Akeega for BRCA-positive metastatic castration-resistant prostate cancer September 15, 2023Vol.49 No.34
Clinical Roundup City of Hope researchers identify biomarkers that may detect risk of advanced prostate cancer in Black men September 08, 2023Vol.49 No.33
Clinical RoundupFree Loss of gene releases mutation-generating protein, rendering cancers resistant to treatment, UTSW researchers find August 11, 2023Vol.49 No.32
Drugs & Targets FDA grants Ambrx Fast Track designation for prostate cancer ADC therapy July 21, 2023Vol.49 No.29
Clinical Roundup Sylvester researchers target treatment-resistant prostate cancer with oral chemo in preclinical study July 14, 2023Vol.49 No.28
Drugs & Targets FDA approves Talzenna with enzalutamide for HRR gene-mutated metastatic castration-resistant prostate cancer June 23, 2023Vol.49 No.25
